0.6898  -0.029 (-4.06%)		05-23 16:00
Open: 0.691 High: 0.72 Volume: 94,902		Pre. Close: 0.719 Low: 0.6602 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	1.12	1-year :	1.41
Resists	First :	0.96	Second :	1.21
Pivot price	0.66
Supports	First :	0.57	Second :	0.47
MAs	MA(5) :	0.7	MA(20) :	0.67
	MA(100) :	0.77	MA(250) :	0.95
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	38.5	D(3) :	28
RSI	RSI(14): 50.6
52-week	High :	3	Low :	0.57

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ADIL ] has closed below upper band by 35.5%. Bollinger Bands are 9.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.72 - 0.72	0.72 - 0.73
Low:	0.65 - 0.66	0.66 - 0.66
Close:	0.68 - 0.69	0.69 - 0.69

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Thu, 15 May 2025
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stock News - GuruFocus

Thu, 15 May 2025
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Thu, 15 May 2025
Adial Pharmaceuticals Advances AUD Drug to Phase 3, Cuts Losses by 66% in Q1 2025 Earnings - Stock Titan

Wed, 14 May 2025
ADIAL PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

Tue, 13 May 2025
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - GlobeNewswire

Thu, 08 May 2025
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	7 (M)
Shares Float	6 (M)
Held by Insiders	1.3 (%)
Held by Institutions	9.3 (%)
Shares Short	140 (K)
Shares Short P.Month	417 (K)

EPS	-2.73
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.62
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-105.9 %
Return on Equity (ttm)	-323.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.27
Qtrly Earnings Growth	0 %
Operating Cash Flow	-7 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.26
PEG Ratio	0
Price to Book value	1.09
Price to Sales	0
Price to Cash Flow	-0.66

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.